X

ATRACURIUM LABATEC IV SOLUTION FOR INJECTION 10MG/ML

Product Information

Registration Status: Active

SIN14836P

ATRACURIUM LABATEC IV SOLUTION FOR INJECTION 10MG/ML is approved to be sold in Singapore with effective from 2015-08-28. It is marketed by SKYQUEST PTE LTD, with the registration number of SIN14836P.

This product contains Atracurium 10mg/ml in the form of INJECTION, SOLUTION. It is approved for INTRAVENOUS use.

This product is manufactured by Hikma Farmaceutica (Portugal) in PORTUGAL.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [PubChem]

Indication

For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Mechanism of Action

Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

Toxicity

Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.

Active Ingredient/Synonyms

1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium | Atracurium besilate | Atracurium dibesylate | Atracurium besylate |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!